Last A$0.07 AUD
Change Today -0.005 / -6.67%
Volume 4.3M
As of 12:10 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/11/14 - A$0.68
52 Week Low
01/30/15 - A$0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, develops human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies in Australia and the United States. Its technologies include HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. The company also provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, it develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer, as well as in the phase II investigator-sponsored trials that focuses on small cell lung cancer. The company has collaboration agreements with AstraZeneca AB to discover and develop novel small molecules against multiple targets; Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer; and IMBcom Asset Management Company for conducting research based upon certain voltage gated ion channel biological targets and library compounds, as well as with University of Queensland for ion channel drug discovery. Alchemia Limited also has research agreement with Monash University; and Cancer Research Technology Limited. The company was founded in 1995 and is headquartered in Brisbane, Australia.

29 Employees
Last Reported Date: 08/29/14
Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$235.7K
Group Financial Controller
Total Annual Compensation: A$193.4K
Vice President of Drug Discovery
Total Annual Compensation: A$224.3K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$223.9K
Compensation as of Fiscal Year 2014.

alchemia ltd (ACL) Key Developments

Alchemia To Raise Funds For VAST

The Board of Alchemia Limited (ASX:ACL) has come to the decision that the best way forward for VAST is to seek external funding for the technology. Evolution Life Science Partners has been appointed to assist Alchemia Limited in this process. Confidential discussions are underway with a number of parties. The close of any potential transaction is targeted prior to the end of June 2015, but Alchemia Limited will continue to assess the viability of this process on a monthly basis and is prepared to terminate it earlier should there be no identifiable corporate transaction to consummate.

Alchemia To Sell Fondaparinux

Alchemia Limited (ASX:ACL) continues to revisit the possible sale of fondaparinux. Alchemia Limited is working with the same advisor previously retained to look at options concerning the possible monetization of fondaparinux and has commenced discussions with potentially interested parties. A transaction will only be entered into if Alchemia Limited believes the price achieved reflects appropriate value of fondaparinux for Alchemia Limited's shareholders at that time. In the event that a sale of fondaparinux does not occur, the Board aims to formally resolve to commence paying dividends from fondaparinux revenues on the basis noted above before the end of calendar year 2015.

Alchemia Considers Strategic Review

Alchemia Limited (ASX:ACL) looks For strategic alternatives. Tracie Ramsdale, Executive Director of Alchemia, said on December 31 that the AUD 6.5 million refund was the result of a successful claim under the Australian R&D tax incentive program for the year ended June 30 2014."This refund has ensured the company has a solid cash position while it continues with its strategic review."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.07 AUD -0.005

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at